PTK2 and ovarian carcinoma: Previous studies indicated that FAK inhibitors might enhance the effect of various chemotherapeutic agents such as paclitaxel and cisplatin in ovarian cancer and pancreatic neuroendocrine tumors, respectively [9, 47].